Notice Number: NOT-FD-20-020
Key Dates
Release Date: March 26, 2020
PAR-20-105
Issued by
FOOD AND DRUG ADMINISTRATION (FDA)
Purpose
This Notice is to extend the 2020 Application Due Date and to update the Scored Review Criteria for the Overall and Admin components for PAR-20-105 "Laboratory Flexible Funding Model (LFFM) (U19) Clinical Trials Not Allowed."
The New 2020 Application Due Date is:
New Application Due Date(s)
May 29, 2020, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
The new Scored Review Criteria for the Overall and Admin components are:
Scored Review Criteria - Overall and Admin
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each.
Effective Use of Grant Funds (10 points)
Is the proposed budget relevant and does it support the scope of all the activities outlined in the application?
Personnel and Resources (20 points)
Are the PD(s)/PI(s), collaborators, and other key personnel well suited to the project, including having appropriate experience and training? Does the applicant appear to have adequate staff and resources (including necessary equipment) to meet the minimum analysis activities of the analytical tracks applied for?
Approach (20 points)
Did the application provide enough detail about the quality management system to provide an understanding of the quality control and assurance measures in place? Do they agree to participate in proficiency tests or competency exercises on an annual basis to maintain competency?
Capability (50 points)
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Is there adequate demonstration of effectiveness in working with other agencies and appropriate organizations to implement the goals of the cooperative agreement - for example: who will collect the required samples? Did the application provide enough detail about how the applicant will execute the activities and projects within the proposal? Are the desired technologies being utilized?
Inquiries
Please direct all inquiries to:
Kiara Fowler
Grants Management Specialist
Office of Operations, Office of Finance Budget & Acquisitions
Office of Acquisitions and Grants Services, HFA-500
U.S. Food and Drug Administration
Tel: 240-402-3099
Kiara.Fowler@fda.hhs.gov
and Human Services (HHS)
